Risk factor
Strong & resilient to price shocks
Profitability factor
Strong growth
About
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology,...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair valu
Target Price
The average target price of IPCALAB.NS is 1503 and suggests 2% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t
Buy
Sell